​

NeoGenomics (NEO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NEO Stock Forecast

NeoGenomics (NEO) stock forecast, based on 29 Wall Street analysts, predicts a 12-month average price target of $12.50, with a high of $14.00 and a low of $11.00. This represents a 9.27% increase from the last price of $11.44.

$11 $12 $13 $14 $15 $16 $17 $18 High: $14 Avg: $12.5 Low: $11 Last Closed Price: $11.44

NEO Stock Rating

NeoGenomics stock's rating consensus is Buy, based on 29 Wall Street analysts. The breakdown includes 1 Strong Buy (3.45%), 20 Buy (68.97%), 7 Hold (24.14%), 1 Sell (3.45%), and 0 Strong Sell (0.00%).

Buy
Total 29 1 7 20 1 Strong Sell Sell Hold Buy Strong Buy

NEO Price Target Upside V Benchmarks

TypeNameUpside
StockNeoGenomics9.27%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks24.65%

Price Target Trends

1M3M12M
# Anlaysts--6
Avg Price Target--$10.67
Last Closing Price$11.44$11.44$11.44
Upside/Downside---6.73%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 26247--13
Jan, 26247--13
Dec, 25247--13
Nov, 25248--14
Oct, 25248--14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 28, 2025Leerink Partners$14.00$9.9241.13%22.38%
Sep 02, 2025Stephens$11.00$8.8124.86%-3.85%
Aug 04, 2025Piper Sandler$11.00$5.6794.00%-3.85%
Jul 30, 2025Morgan Stanley$8.00$5.1056.86%-30.07%
Jul 29, 2025Needham$8.00$5.2552.38%-30.07%
May 06, 2025David WestenbergPiper Sandler$12.00$7.8453.06%4.90%
Jan 11, 2025Mark MassaroBTIG$18.00$14.7721.87%57.34%
Jul 30, 2024Mike MatsonNeedham$19.00$14.6429.78%66.08%
May 02, 2024Mark MassaroBTIG$21.00$13.9650.43%83.57%
Aug 21, 2023Mason CarricoStephens$18.00$14.0827.84%57.34%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 07, 2026Cowen & Co.BuyBuyhold
Sep 12, 2025Cowen & Co.BuyBuyhold
Sep 02, 2025StephensOverweightOverweighthold
May 15, 2025GuggenheimNeutralinitialise
May 06, 2025Piper SandlerOverweightOverweighthold
Jan 11, 2025BTIGBuyBuyhold
Sep 24, 2024StephensBuyBuyhold
Sep 24, 2024BenchmarkBuyBuyhold
Jul 30, 2024NeedhamBuyBuyhold
May 02, 2024BTIGBuyBuyhold

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 $1 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-0.35$-5.80$-3.50$-3.10$-4.20--
Avg Forecast$-0.27$-0.68$-0.17$0.10$0.20$0.36$0.51
High Forecast$-0.27$-0.67$-0.16$0.12$0.24$0.54$0.51
Low Forecast$-0.27$-0.69$-0.20$0.09$0.13$0.13$0.50
Surprise %29.63%752.94%1958.82%-3200.00%-2200.00%--

Revenue Forecast

$450M $550M $650M $750M $850M $950M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$484.33M$509.73M$591.64M$660.57M$727.33M--
Avg Forecast$484.65M$501.06M$588.86M$661.89M$733.08M$806.77M$863.51M
High Forecast$487.93M$505.90M$591.66M$664.30M$735.03M$807.37M$904.01M
Low Forecast$481.01M$495.67M$584.96M$660.51M$731.17M$806.17M$823.01M
Surprise %-0.07%1.73%0.47%-0.20%-0.78%--

Net Income Forecast

$-250M $-180M $-110M $-40M $30M $100M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-8.35M$-144.25M$-87.97M$-78.73M$-108.03M--
Avg Forecast$-77.40M$-167.24M$-87.97M$13.05M$23.19M$42.38M$64.01M
High Forecast$-20.95M$-133.79M$-70.37M$15.11M$30.09M$68.11M$64.44M
Low Forecast$-133.85M$-200.68M$-105.56M$10.99M$16.30M$16.65M$63.35M
Surprise %-89.22%-13.74%--703.26%-565.73%--

NEO Forecast FAQ

Is NeoGenomics stock a buy?

NeoGenomics stock has a consensus rating of Buy, based on 29 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 20 Buy, 7 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that NeoGenomics is a favorable investment for most analysts.

What is NeoGenomics's price target?

NeoGenomics's price target, set by 29 Wall Street analysts, averages $12.5 over the next 12 months. The price target range spans from $11 at the low end to $14 at the high end, suggesting a potential 9.27% change from the previous closing price of $11.44.

How does NeoGenomics stock forecast compare to its benchmarks?

NeoGenomics's stock forecast shows a 9.27% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the diagnostics & research stocks industry (24.65%).

What is the breakdown of analyst ratings for NeoGenomics over the past three months?

  • February 2026: 15.38% Strong Buy, 30.77% Buy, 53.85% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 15.38% Strong Buy, 30.77% Buy, 53.85% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 15.38% Strong Buy, 30.77% Buy, 53.85% Hold, 0% Sell, 0% Strong Sell.

What is NeoGenomics’s EPS forecast?

NeoGenomics's average annual EPS forecast for its fiscal year ending in December 2026 is $0.36, marking a -108.57% decrease from the reported $-4.2 in 2025. Estimates for the following years are.

What is NeoGenomics’s revenue forecast?

NeoGenomics's average annual revenue forecast for its fiscal year ending in December 2026 is $806.77M, reflecting a 10.92% increase from the reported $727.33M in 2025. The forecast for.

What is NeoGenomics’s net income forecast?

NeoGenomics's net income forecast for the fiscal year ending in December 2026 stands at $42.38M, representing a -139.23% decrease from the reported $-108M in 2025. Projections indicate .